



Molecular Immunotherapy of Solid Tumors

Guest Editor:

Dr. Raheleh Roudi

Molecular Imaging Program at
Stanford, Department of
Radiology, Stanford University,
Stanford, CA 94305, USA

Deadline for manuscript
submissions:

closed (15 August 2023)

Message from the Guest Editor

Dear Colleagues,

Cancer immunotherapy is transforming multidisciplinary cancer care and opening new therapeutic avenues. The current types of immunotherapies that have been explored include monoclonal antibodies (mAb), immune-checkpoint inhibitors (ICIs), oncolytic viral platforms (OV), cancer vaccines, adoptive cell therapy (ACT), and various combinatorial approaches. The purpose of this Special Issue is to define the role of molecular immunotherapies in solid tumors, including (1) mAb in cancer treatment; (2) the contribution of ICIs in the progress of cancer therapies; (3) cancer vaccines in solid tumors; (4) predictive biomarkers for checkpoint-inhibitor-based immunotherapy; (5) drug resistance and immunotherapies; and (6) the combination of immunotherapies with conventional cancer treatments. This Special Issue welcomes both original research articles and reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)